PARVOVIRUS B19 PROMOTER AT MAP UNIT-6 CONFERS AUTONOMOUS REPLICATION COMPETENCE AND ERYTHROID SPECIFICITY TO ADENOASSOCIATED VIRUS-2 IN PRIMARY HUMAN HEMATOPOIETIC PROGENITOR CELLS

Citation
Xs. Wang et al., PARVOVIRUS B19 PROMOTER AT MAP UNIT-6 CONFERS AUTONOMOUS REPLICATION COMPETENCE AND ERYTHROID SPECIFICITY TO ADENOASSOCIATED VIRUS-2 IN PRIMARY HUMAN HEMATOPOIETIC PROGENITOR CELLS, Proceedings of the National Academy of Sciences of the United Statesof America, 92(26), 1995, pp. 12416-12420
Citations number
44
Categorie Soggetti
Multidisciplinary Sciences
ISSN journal
00278424
Volume
92
Issue
26
Year of publication
1995
Pages
12416 - 12420
Database
ISI
SICI code
0027-8424(1995)92:26<12416:PBPAMU>2.0.ZU;2-Z
Abstract
The pathogenic human parvovirus B19 is an autonomously replicating vir us with a remarkable tropism for human erythroid progenitor cells, Alt hough the target cell specificity for B19 infection has been suggested to be mediated by the erythrocyte P-antigen receptor (globoside), a n umber of nonerythroid cells that express this receptor are nonpermissi ve for B19 replication, To directly test the role of expression from t he B19 promoter at map unit 6 (B19p6) in the erythroid cell specificit y of B19, we constructed a recombinant adenoassociated virus 2 (AAV), in which the authentic AAV promoter at map unit 5 (AAVp5) was replaced by the B19p6 promoter, Although the wild-type (wt) AAV requires a hel per virus for its optimal replication, we hypothesized that inserting the B19p6 promoter in a recombinant AAV would permit autonomous viral replication, but only in erythroid progenitor cells. In this report, w e provide evidence that the B19p6 promoter is necessary and sufficient to impart autonomous replication competence and erythroid specificity to AAV in primary human hematopoietic progenitor cells, Thus, express ion from the B19p6 promoter plays an important role in post-P-antigen receptor erythroid-cell specificity of parvovirus B19. The AAV-B19 hyb rid vector system may also prove to be useful in potential gene therap y of human hemoglobinopathies.